Clinical Utility of Heavy/Light Chain Assay for Evaluation and Prognostication in Multiple Myeloma Patients

Evaluation of the clinical utility of the novel heavy/light chain immunoassay for the assessment of multiple myeloma patients.The novel heavy/light chain allows accurate measurement of monoclonal immunoglobulins and can be more sensitive than standard techniques at detecting residual disease. Abnormal heavy/light chain ratios and immunoglobulin isotype pair suppression may have prognostic significance for multiple myeloma patients.